Robot assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor

Dogra, Prem Nath; Singh, Prabhjot; Saini, Arunima; Regmi, K Subodh; Singh, Bora G; Nayak, Brusabhanu

doi:10.4103/0974-7796.120289

Cited by 19 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 39 ] Open RPLND is the current gold standard of treatment. [ 40 ] However, it entails a high morbidity and long recovery period. This has prompted the application of minimally invasive modalities for RPLND.…”

Section: Resultsmentioning

confidence: 99%

Role of laparoscopy in the era of robotic surgery in urology in developing countries

Bansal

Chaturvedi

Maheshwari

et al. 2021

Indian Journal of Urology

View full text Add to dashboard Cite

With the rapid expansion of robotic platforms in urology, there is an urgent and unmet need to review its cost and benefits in comparison to the traditional laparoscopy, especially in reference to a developing country. A nonsystematic review of the literature was conducted to compare the outcomes of pure laparoscopic and robot-assisted urologic procedures. Available literature over the past 30 years was reviewed. Robot-assisted surgery and laparoscopy were found to have similar outcomes in the areas of radical prostatectomy, partial and radical nephrectomy, radical cystectomy, retroperitoneal lymph node (LN) dissection, inguinal LN dissection, donor nephrectomy, and kidney transplantation. Robot-assisted surgery was found to be significantly costlier than pure laparoscopy. In the absence of a clear advantage of robot-assisted surgery over pure laparoscopy, lack of widespread availability and the currently prohibitive cost of robotic technology, laparoscopic urological surgery has a definite role in the developing world.

show abstract

Section: Resultsmentioning

confidence: 99%

Role of laparoscopy in the era of robotic surgery in urology in developing countries

Bansal

Chaturvedi

Maheshwari

et al. 2021

Indian Journal of Urology

View full text Add to dashboard Cite

show abstract

“…reported first RA-RPLND in 2006[ 12 ] and subsequently many other investigators reported small case series of RA-RPLND. [ 13 14 15 ] However, most investigators have reported their experience of RA-RPLND in CS IA, IB, IIA, IIB, IIC. There are only a few studies, which reported experience of RA-RPLND for postchemotherapy residual mass.…”

Section: Discussionmentioning

confidence: 99%

Robot-assisted retroperitoneal lymph node dissection: Feasibility and outcome in postchemotherapy residual mass in testicular cancer

et al. 2017

View full text Add to dashboard Cite

Introduction:We aimed to evaluate the surgical feasibility, complication, and oncological outcome of robot-assisted retroperitoneal lymph node dissection (RA-RPLND) in patients of testicular tumor with postchemotherapy residual retroperitoneal mass.Methods:A total of 13 patients underwent RA-RPLND between January 2012 and September 2016 at our institute. A study was started on December 2015, so data were collected retrospectively and prospectively regarding patient demography, tumor characteristics, surgical, pathological outcome, and oncological outcome.Results:RA-RPLND was successfully completed in all the 13 patients. Lateral approach was used in initial 12 patients with unilateral dissection in 11 patients and bilateral dissection after in 1 patient after repositioning in bilateral position. Supine robotic approach used in 1 patient. Median operative time was 200 min, median estimated blood loss was 120 ml, and median length of hospital stay was 4 days. The median yield of lymph node was 20. Three patients had positive lymph nodes, all had teratoma germ cell tumor. Ten patients had only necrosis in lymph nodes. After median follow-up 23 months (range 3-58 months), no systemic or retroperitoneal recurrence was found. Four patients developed chyle leak. One patient was managed conservatively with diet modification, one with intranodal lipiodol lymphangiography and two patients were managed surgically.Conclusion:RA-RPLND is safe and feasible for postchemotherapy residual mass with accepted compilation rate, but larger studies are required to establish its diagnostic and therapeutic utility along with safety of the procedure.

show abstract

“…The surgical robot, equipped with a three-dimensional magnified vision and scaled movements of the instruments with an elimination of hand tremor, offers a great promise to overcome these hurdles. The initial data on robot-assisted RPLND (R-RPLND) is in the form of case reports[ 43 ] and small case series. [ 44 ] These studies have stated the feasibility of R-RPLND in low stage NSGCT.…”

Section: Robotic Surgery For Testicular Cancermentioning

confidence: 99%

Robotics in urologic oncology

Jain

Gautam

2015

J Min Access Surg

View full text Add to dashboard Cite

Robotic surgery was initially developed to overcome problems faced during conventional laparoscopic surgeries and to perform telesurgery at distant locations. It has now established itself as the epitome of minimally invasive surgery (MIS). It is one of the most significant advances in MIS in recent years and is considered by many as a revolutionary technology, capable of influencing the future of surgery. After its introduction to urology, robotic surgery has redefined the management of urological malignancies. It promises to make difficult urological surgeries easier, safer and more acceptable to both the surgeon and the patient. Robotic surgery is slowly, but surely establishing itself in India. In this article, we provide an overview of the advantages, disadvantages, current status, and future applications of robotic surgery for urologic cancers in the context of the Indian scenario.

show abstract

Robot assisted laparoscopic retroperitoneal lymph node dissection in testicular tumor

Cited by 19 publications

References 4 publications

Role of laparoscopy in the era of robotic surgery in urology in developing countries

Role of laparoscopy in the era of robotic surgery in urology in developing countries

Robot-assisted retroperitoneal lymph node dissection: Feasibility and outcome in postchemotherapy residual mass in testicular cancer

Robotics in urologic oncology

Contact Info

Product

Resources

About